QTRX / Quanterix Corporation (QTRX) CEO Masoud Toloue on Q2 2022 Results - Earnings Call Transcript

Quanterix specializes in ultra-sensitive digital immunoassay platforms for early disease detection, potentially transforming disease management. The c more_horizontal

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares t more_horizontal

Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with more_horizontal

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revis more_horizontal

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detec more_horizontal

Quanterix Corporation (NASDAQ:QTRX ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Mike Doyle - CFO Masoud Toloue - Pres more_horizontal

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares t more_horizontal

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revis more_horizontal